Floreat Medica Research & Development (R&D) is focused towards developing new products, improving existing products as well as drug delivery systems and expanding product applications.
In-house R&D forms the backbone of our operations. With almost 5-6% of the company turnover being invested towards R&D each year, our strategy focuses on:
In addition, for our international business, our R&D team works with our strategic partners to file Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAs) in the US, and seek marketing authorizations in Europe and file product registrations in other jurisdictions.
We have earned a name for maintaining world-class quality across all our manufacturing units, products and services. We have consistently introduced more than 40 products annually, over the last decade.
We have been granted about 100 patents. Patent filing includes drug substances, drug products, platform technologies, IP on polymorphs and crystallinity, and medical devices.
We also leverage our R&D efforts to provide our customers with technical dossiers, plant layouts for pharmaceutical product manufacturing, development of processes and regulatory batches.